
Albert Bourla, Pfizer CEO (AP Photo/Markus Schreiber)
Updated: Pfizer sticks to 2025 projections as Covid sales stabilize, R&D revamp continues
Pfizer’s high-profile, high-volatility Covid-19 franchise stabilized at the end of 2024, as the New York drugmaker pursues a revamp of its R&D operations and continues …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.